Log In
Print this Print this

enfortumab vedotin (ASG-22CE, ASG-22ME) (formerly ASG-22M6E)

  Manage Alerts
Collapse Summary General Information
Company Seattle Genetics Inc.
DescriptionAntibody-drug conjugate (ADC) composed of an anti-nectin-4 (PRR4) mAb and monomethyl auristatin E (MMAE)
Molecular Target Nectin-4 (PRR4)
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPhase I
Standard IndicationSolid tumors
Indication DetailsTreat solid tumors
Regulatory Designation
PartnerAstellas Pharma Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today